BOOK
Clinical Approaches to Oral Mucosal Disorders: Part II, An Issue of Dental Clinics of North America, E-Book
(2014)
Additional Information
Book Details
Abstract
Part II of our important volume on oral mucosal disorders, in this issue we cover: oral herpes virus infections, recurrent aphthous stomatitis, lichen planus/lichenoid mucositis, pediatric soft tissue diagnosis, oral cancer, chemotherapy/radiation induced oral mucositis, bisphosphonate related osteonecrosis of jaws/anti-resorptive drug related osteonecrosis of the jaw, oral graft-versus-host disease, human papillomavirus, perioral lesions and dermatoses, and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Clinical Approaches to Oral Mucosal Disorders: Part II\r | i | ||
| copyright\r | ii | ||
| Contributors | iii | ||
| Contents | vii | ||
| Dental Clinics Of North America\r | x | ||
| Preface | xi | ||
| Dedication | xi | ||
| Update on Oral Herpes Virus Infections | 265 | ||
| Key points | 265 | ||
| Introduction | 265 | ||
| HSV | 266 | ||
| Primary herpes simplex infections | 266 | ||
| Recurrent herpes simplex infection | 267 | ||
| Diagnosis | 270 | ||
| Differential Diagnosis | 270 | ||
| Laboratory Diagnosis | 271 | ||
| Virologic tests | 271 | ||
| Cytology smears | 271 | ||
| Immunomorphologic tests | 271 | ||
| Polymerase chain reaction test | 271 | ||
| Serologic tests | 271 | ||
| VZV | 272 | ||
| Varicella | 272 | ||
| HZ | 272 | ||
| EBV | 273 | ||
| CMV | 274 | ||
| HHV-6 | 275 | ||
| HHV-7 | 275 | ||
| HHV-8 | 276 | ||
| Summary | 276 | ||
| References | 276 | ||
| Recurrent Aphthous Stomatitis | 281 | ||
| Key points | 281 | ||
| Introduction | 281 | ||
| Epidemiology | 282 | ||
| Predisposing etiologic factors | 282 | ||
| Local Factors | 283 | ||
| Microbial Factors | 284 | ||
| Underlying Disease | 285 | ||
| Hereditary and Genetic Factors | 286 | ||
| Allergic Factors | 287 | ||
| Immunologic Factors | 287 | ||
| Nutritional Factors | 288 | ||
| Psychological Stress | 288 | ||
| Other Factors | 288 | ||
| Clinical manifestation and pathogenesis | 289 | ||
| Management | 289 | ||
| Summary | 292 | ||
| References | 292 | ||
| Oral Lichen Planus and Lichenoid Mucositis | 299 | ||
| Key points | 299 | ||
| Introduction | 299 | ||
| Nature of Problem and Definition | 299 | ||
| Prevalence/Incidence | 300 | ||
| Cause and Pathogenesis | 300 | ||
| Symptoms | 301 | ||
| Clinical findings | 302 | ||
| Physical Examination | 302 | ||
| Diagnostic Modalities | 304 | ||
| Pathology | 304 | ||
| Diagnostic dilemma: a premalignant lesion | 305 | ||
| Comorbidities | 306 | ||
| Lichenoid Drug Reactions | 306 | ||
| Hepatitis C and OLP | 307 | ||
| Management | 307 | ||
| Goals | 307 | ||
| Pharmacologic Strategies: Topical Medications | 308 | ||
| Pharmacologic Strategies: Systemic Therapies | 308 | ||
| Summary | 310 | ||
| References | 310 | ||
| Oral Cancer | 315 | ||
| Key points | 315 | ||
| Anatomic sites | 317 | ||
| Stage at diagnosis and survival | 319 | ||
| TNM staging | 319 | ||
| Cause and risk factors | 320 | ||
| Immune system | 320 | ||
| Tobacco | 320 | ||
| Oral lichen planus | 321 | ||
| Nutrition | 321 | ||
| Viruses | 321 | ||
| Clinical assessment | 322 | ||
| Signs and symptoms | 322 | ||
| Erythroleukoplakia and erythroplakia | 325 | ||
| Erythroplakia with ulceration | 325 | ||
| PVL | 325 | ||
| Candidiasis (candidosis), leukoplakia, and erythroplakia | 325 | ||
| Delay in diagnosis | 326 | ||
| Oral carcinogenesis, epithelial dysplasia, and malignant transformation | 327 | ||
| Molecular progression | 328 | ||
| Genomics and proteomics | 328 | ||
| Precancerous classification (PMDs) | 329 | ||
| Diagnosis and management | 330 | ||
| Incisional and excisional scalpel or punch biopsy | 330 | ||
| Diagnostic adjunctive techniques | 330 | ||
| Cytology and brush biopsy | 330 | ||
| Fine-needle aspiration | 331 | ||
| Toluidine blue | 331 | ||
| Visualization-based adjunctive techniques | 331 | ||
| Monoclonal antibodies | 332 | ||
| Imaging | 332 | ||
| Chemoprevention | 333 | ||
| Chemoprevention of Oral Leukoplakia Remains Experimental | 333 | ||
| Workup for patients with oral SCCs | 333 | ||
| Treatment | 333 | ||
| Follow-up | 334 | ||
| References | 334 | ||
| Chemotherapy or Radiation-Induced Oral Mucositis | 341 | ||
| Key points | 341 | ||
| Introduction, epidemiology, and pathogenesis | 341 | ||
| Morbidity of oral mucositis | 342 | ||
| Pain | 342 | ||
| Nutritional Compromise | 342 | ||
| Quality of Life | 342 | ||
| Impact on Cancer Therapy | 342 | ||
| Infection | 342 | ||
| Impact on Oral Health | 344 | ||
| Economic Impact | 344 | ||
| Clinical findings | 344 | ||
| Management of oral mucositis | 345 | ||
| Symptom Management | 345 | ||
| Targeted Therapeutic Interventions | 346 | ||
| Cryotherapy | 346 | ||
| Low-level laser therapy | 347 | ||
| Growth factors | 347 | ||
| Antiinflammatory agents | 347 | ||
| Antimicrobial agents | 347 | ||
| Summary | 348 | ||
| References | 348 | ||
| Oral Graft-Versus-Host Disease | 351 | ||
| Key points | 351 | ||
| Introduction | 351 | ||
| Pathobiology and incidence of GVHD | 352 | ||
| aGVHD | 353 | ||
| cGVHD | 354 | ||
| Oral GVHD | 355 | ||
| Incidence | 355 | ||
| Clinical Findings | 355 | ||
| Diagnosis and Assessment | 356 | ||
| Impact of GVHD | 358 | ||
| Overall Survival | 358 | ||
| Quality of Life | 359 | ||
| Oral GVHD | 359 | ||
| Prevention and management of GVHD | 359 | ||
| Management Principles | 359 | ||
| Prophylaxis | 360 | ||
| Systemic Therapy | 360 | ||
| Management of oral GVHD | 361 | ||
| Pharmacologic Strategies | 361 | ||
| Nonpharmacologic Strategies | 362 | ||
| Late complications of oral GVHD | 363 | ||
| Summary | 363 | ||
| References | 364 | ||
| Antiresorptive Drug–Related Osteonecrosis of the Jaw | 369 | ||
| Key points | 369 | ||
| Introduction | 369 | ||
| Antiresorptive Drugs Associated with ONJ | 370 | ||
| BP | 370 | ||
| Anti-RANK ligand: denosumab | 370 | ||
| Differences between BP and denosumab | 371 | ||
| Epidemiology | 371 | ||
| Worldwide incidence | 372 | ||
| Clinical parameters | 373 | ||
| Diagnostic Guidelines and Staging of ARONJ | 373 | ||
| Imaging | 373 | ||
| Pathogenicity | 374 | ||
| Impaired Epithelial Repair | 374 | ||
| Bacterial Colonization and Biofilm | 375 | ||
| Immunosuppression | 375 | ||
| Diagnostic dilemmas | 376 | ||
| Management strategies | 377 | ||
| Surgical Strategies | 377 | ||
| Nonsurgical and Adjunctive Strategies | 379 | ||
| Summary | 379 | ||
| References | 380 | ||
| The Role of Human Papillomavirus in Oral Disease | 385 | ||
| Key points | 385 | ||
| Introduction | 385 | ||
| The virus | 386 | ||
| HPV infection | 387 | ||
| HPV immunology | 388 | ||
| HPV transmission | 388 | ||
| Epidemiology | 388 | ||
| Oral clinical lesions associated with HPV | 389 | ||
| Verruca Vulgaris (Common Wart) | 389 | ||
| Multifocal Epithelial Hyperplasia (Heck Disease) | 390 | ||
| Condyloma Accuminatum (Venereal Wart) | 390 | ||
| Oral squamous papilloma | 392 | ||
| Potentially malignant papillomatous lesions | 392 | ||
| Oral leukoplakia and head and neck squamous cell carcinoma | 392 | ||
| Treatment of oral HPV-related clinical lesions | 394 | ||
| Prevention | 395 | ||
| Summary | 395 | ||
| Acknowledgments | 396 | ||
| References | 396 | ||
| Perioral Lesions and Dermatoses | 401 | ||
| Key points | 401 | ||
| Index | 455 |